Join the Oncology Voice Network. Join for Free
How Biomarker Testing Drives the Use of Targeted Therapies

How Biomarker Testing Drives the Use of Targeted Therapies


Share This Article


ONS member Cyndy Simonson, MS, APRN-BC, AOCN®, oncology nurse practitioner who is the nursing editor at Duke Regional Hospital in Durham, NC, and member of the North Carolina Triangle ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss biomarker testing for patients with cancer and how it affects targeted therapy regimens during treatment. The advertising messages in this episode are paid for by G1 Therapeutics, Inc. 

Click for Source

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN